Impact of confinement housing on study end-points in the calf model of cryptosporidiosis

Prophylactic and therapeutic efficacy of clinoptilolite against Cryptosporidium parvum in experimentally challenged neonatal lambs

This study was designed to test the prophylactic and therapeutic efficacy of clinoptilolite against Cryptosporidium (C.) parvum infection in lambs. Within the first day of life, three groups of 10 lambs were each inoculated with 1 × 10⁶ oocysts of C. parvum. The prophylactic (PROP) group received orally clinoptilolite supplemented at a rate of 3% to the colostrum within the first day of life before inoculation and then to milk replacer for two weeks. The therapeutic (TREA) group was supplemented with the same rate, route and duration of clinoptilolite, starting from the day of the first appearance of oocysts in the faeces. The positive control group (pCON) was left untreated and fed only the basal diet. Disease development and clinoptilolite efficacy were assessed daily by evaluating oocyst per gram of faeces (OPG) counts, faecal consistent score (FCS), and clinical health score (CHS) from day -1 to 20 days post inoculation. A significantly (p < 0.001) lower OPG value was found in the PROP and TREA groups in comparison to the pCON group. The FCS and CHS were decreased in the PROP (p < 0.01 and p < 0.001) and TREA (p < 0.05 and p < 0.001) groups compared to the pCON group, respectively. The percentage efficacy of clinoptilolite was calculated to be 97.4 % in the PROP group and 91.6 % in the TREA group. In conclusion, this study proved for the first time that clinoptilolite has promising prophylactic and therapeutic activities against C. parvum in experimentally infected lambs.

Efficacy of halofuginone products to prevent or treat cryptosporidiosis in bovine calves: a systematic review and meta-analyses

A prior systematic review on the efficacy of halofuginone (HFG) treatment to prevent or treat cryptosporidiosis in bovine calves was inconclusive. We undertook an updated synthesis and meta-analyses on key outcomes for the treatment of calves with HFG. Evaluated outcomes were oocyst shedding, diarrhoea, mortality and weight gain. Experiments had to describe results for same age animals in contemporary arms. Most doses were 100-150 mcg kg-1 day-1. Results were subgrouped by study design, experiments with the lowest risk of bias and lack of industry funding. Eighteen articles were found that described 25 experiments. Most evidence came from randomized controlled trials in Europe. Significantly lower incidence of oocyst shedding, diarrhoea burden and mortality was reported when treatment started before calves were 5 days old. Most studies reported on outcomes for animals up to at least 28 days old. Publication bias was possible in all outcomes and seemed especially likely for diarrhoea outcomes. Beneficial results when HFG treatment was initiated in calves older than 5 days were also found. Prophylactic treatment to prevent cryptosporidiosis is effective in preventing multiple negative outcomes and is beneficial to calf health and will result in a reduction of environmental contamination by Cryptosporidium oocysts.